Coronavirus Update: Pfizer, BioNTech Hit Ground Running On Vaccine EUA
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.
You may also be interested in...
Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.
The European Medicines Agency will continue working over the Christmas period so that it can complete its assessment of the newly filed marketing applications for BioNTech/Pfizer’s and Moderna’s COVID-19 vaccines as soon possible.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.